8-K: Inhibrx Announces Promising Preliminary Data for Ozekibart in Colorectal Cancer Treatment

Inhibrx Biosciences reported positive preliminary results from a Phase 1 trial of ozekibart in combination with FOLFIRI for advanced colorectal cancer, showing encouraging disease control and responses.

Summary

• Inhibrx Biosciences announced preliminary efficacy and safety data from a Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic colorectal cancer.
• The trial assessed 10 patients out of 13 who received at least one dose of ozekibart.
• Results showed one complete response (CR), three partial responses (PR), and six cases of stable disease (SD).
• Durable disease control lasting 180 days was observed in 46.2% of patients.
• The median progression-free survival (PFS) was 7.85 months.
• All patients had received at least one prior line of systemic therapy, with a median of two prior lines.
• Ozekibart-related treatment-emergent adverse events (TEAEs) were reported in 84.6% of patients, with most being grade 1 or 2 in severity.
• Grade 3 TEAEs were observed in 30.8% of patients.
• The most common ozekibart-related TEAEs included nausea, increased alanine aminotransferase, diarrhea, and fatigue.
• A new expansion cohort is being initiated to validate these findings in a more uniform patient population, with up to 50 patients expected to enroll and data anticipated in the third quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents positive preliminary clinical trial results with encouraging efficacy and manageable safety, which is likely to be viewed favorably by investors. The company is also moving forward with an expansion cohort, indicating confidence in the drug's potential.

Positives

• The trial demonstrated a complete response in one patient and partial responses in three patients, indicating potential efficacy.
• A significant portion of patients, 46.2%, achieved durable disease control for at least 180 days.
• The median progression-free survival of 7.85 months is encouraging for this patient population.
• Most adverse events were low-grade, suggesting a manageable safety profile.
• The company is moving forward with an expansion cohort to further validate the results.

Negatives

• 84.6% of patients experienced treatment-emergent adverse events (TEAEs).
• 30.8% of patients experienced grade 3 TEAEs.
• Common adverse events included nausea, increased alanine aminotransferase, diarrhea, and fatigue.

Risks

• The results are preliminary and may not be representative of final data or data in later clinical trials.
• There are risks and uncertainties inherent in the company's business, including the initiation, timing, progress, and results of clinical trials.
• Unexpected adverse side effects or inadequate efficacy of the therapeutic candidate could limit its development.
• The company's programs and prospects could be negatively impacted by developments relating to its competitors.
• Regulatory approvals may not be granted or may be delayed.
• The company may not realize the benefits associated with orphan drug designation.

Future Outlook

Inhibrx plans to validate the preliminary findings of the ozekibart trial through an expansion cohort of up to 50 patients, with data expected in the third quarter of 2025. The company is also continuing its Phase 2 trial of ozekibart in chondrosarcoma, with a data readout expected in the middle of 2025.

Management Comments

• Josep Garcia, Chief Clinical Development Officer at Inhibrx, stated that the interim results underscore the potential of ozekibart to provide meaningful clinical benefit for patients with advanced solid tumors.
• Josep Garcia also mentioned that they are encouraged by the durable disease control observed and look forward to further evaluating these findings in the expansion cohort.

Industry Context

The announcement is significant as colorectal cancer is a major global health concern with limited effective therapies beyond the second-line setting. The positive preliminary results for ozekibart could position Inhibrx as a key player in the development of new treatments for this disease.

Comparison to Industry Standards

• The reported complete response rate of 10% and partial response rate of 30% in this heavily pretreated patient population is encouraging when compared to historical data for similar patient groups.
• The median progression-free survival of 7.85 months is competitive with other targeted therapies in advanced colorectal cancer.
• While direct comparisons are difficult without full trial data, the results suggest that ozekibart may offer a meaningful benefit over existing treatments, particularly in patients who have failed prior FOLFIRI-based treatments.
• Companies like Eli Lilly with their drug Cyramza and Bayer with Stivarga are competitors in the advanced colorectal cancer space, and the results of ozekibart will be closely watched in comparison to these established treatments.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with advanced colorectal cancer may benefit from the development of ozekibart.
• Employees of Inhibrx may be motivated by the positive progress of the drug development program.
• The results could impact the company's relationships with potential partners and investors.

Next Steps

• Inhibrx will initiate a new expansion cohort to validate the preliminary findings.
• The expansion cohort is expected to enroll up to 50 patients.
• Data from the expansion cohort is anticipated in the third quarter of 2025.
• The company will continue its Phase 2 trial of ozekibart in chondrosarcoma, with a data readout expected in the middle of 2025.

Key Dates

Keywords

ozekibart, INBRX-109, colorectal cancer, CRC, Phase 1 trial, FOLFIRI, oncology, clinical trial, biopharmaceutical, metastatic cancer